Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 10 04:00PM ET
25.59
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-2.21 Insider Own35.44% Shs Outstand80.50M Perf Week0.12%
Market Cap2.21B Forward P/E- EPS next Y-1.49 Insider Trans-0.06% Shs Float55.83M Perf Month0.87%
Income-190.42M PEG- EPS next Q-0.51 Inst Own61.99% Short Float5.68% Perf Quarter54.72%
Sales174.91M P/S12.65 EPS this Y14.13% Inst Trans1.28% Short Ratio1.71 Perf Half Y69.81%
Book/sh3.85 P/B6.65 EPS next Y24.27% ROA-39.26% Short Interest3.17M Perf Year83.05%
Cash/sh3.15 P/C8.12 EPS next 5Y21.00% ROE-50.37% 52W Range9.90 - 25.61 Perf YTD58.65%
Dividend Est.- P/FCF- EPS past 5Y4.07% ROI-56.42% 52W High-0.08% Beta0.20
Dividend TTM- Quick Ratio3.94 Sales past 5Y51.62% Gross Margin93.26% 52W Low158.48% ATR (14)0.20
Dividend Ex-Date- Current Ratio4.19 EPS Y/Y TTM5.92% Oper. Margin-118.09% RSI (14)85.58 Volatility0.13% 0.17%
Employees355 Debt/Eq0.08 Sales Y/Y TTM26.51% Profit Margin-108.86% Recom2.71 Target Price26.40
Option/ShortYes / No LT Debt/Eq0.07 EPS Q/Q14.02% Payout- Rel Volume0.00 Prev Close25.59
Sales Surprise-0.31% EPS Surprise6.42% Sales Q/Q34.55% EarningsMay 01 Avg Volume1.85M Price25.59
SMA200.32% SMA5020.33% SMA20061.93% Trades Volume1,596,089 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Neutral $14
Oct-30-23Upgrade Piper Sandler Neutral → Overweight $23
Aug-10-23Upgrade Stifel Hold → Buy $14 → $20
Jan-04-23Upgrade Guggenheim Neutral → Buy $22
Aug-29-22Initiated Cowen Outperform $25
Aug-05-22Upgrade JMP Securities Mkt Perform → Mkt Outperform $23
Feb-28-22Downgrade Barclays Equal Weight → Underweight $11 → $6
Nov-08-21Downgrade Stifel Buy → Hold $60 → $10
Nov-08-21Downgrade Canaccord Genuity Buy → Hold $72 → $12
Nov-08-21Downgrade Barclays Overweight → Equal Weight $50 → $11
Jun-11-24 08:30AM
Jun-03-24 07:00AM
May-23-24 01:15PM
May-10-24 01:54PM
09:30AM
08:50AM Loading…
08:50AM
Apr-30-24 07:10AM
07:03AM
07:02AM
07:00AM
03:41AM
Apr-29-24 02:36PM
02:17PM
01:41PM
01:02PM
12:17PM Loading…
12:17PM
12:16PM
11:19AM
10:46AM
10:33AM
09:57AM
09:02AM
08:54AM
07:29AM
07:29AM
07:29AM
07:18AM
07:06AM
07:00AM
Apr-24-24 10:01AM
10:39AM Loading…
Apr-21-24 10:39AM
Apr-09-24 07:00AM
Mar-07-24 11:31AM
Mar-04-24 08:28PM
Feb-28-24 09:55AM
Feb-27-24 07:00AM
Feb-12-24 09:55AM
Feb-07-24 09:20AM
08:28AM
12:33AM
Feb-06-24 07:00AM
Feb-01-24 04:50PM
07:00AM
Jan-30-24 10:01AM
Jan-18-24 11:13AM
Jan-08-24 07:00AM
Jan-05-24 07:00AM
Jan-02-24 07:00AM
Dec-15-23 07:06AM
Dec-02-23 07:08AM
Nov-29-23 11:30AM
07:00AM
Nov-07-23 07:00AM
Nov-01-23 03:03AM
Oct-31-23 07:25AM
04:51AM
01:16AM
Oct-30-23 08:15AM
07:01AM
07:00AM
Oct-16-23 12:39PM
Oct-05-23 11:38AM
Sep-29-23 09:00AM
Sep-22-23 12:02PM
11:46AM
Sep-15-23 05:00PM
Sep-08-23 11:30AM
Aug-21-23 07:43PM
Aug-19-23 07:40AM
Aug-18-23 04:05PM
Aug-11-23 03:30PM
Aug-10-23 08:13AM
Aug-09-23 08:50AM
07:00AM
Aug-03-23 04:15PM
Aug-02-23 07:00AM
Jun-09-23 09:02AM
Jun-02-23 11:31AM
May-25-23 05:00PM
May-23-23 07:00AM
May-08-23 01:31PM
07:00AM
May-04-23 05:38AM
May-03-23 08:15AM
07:00AM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
07:00AM
Apr-19-23 07:00AM
Apr-18-23 06:53AM
Mar-23-23 11:30AM
Mar-16-23 05:25PM
Mar-15-23 11:52AM
06:28AM
Mar-14-23 05:53PM
05:32PM
04:26AM
Mar-09-23 11:30AM
Mar-01-23 07:00AM
Feb-27-23 07:00AM
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera's switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Thomas PatrickChief Financial OfficerFeb 16 '24Sale15.623,01047,00980,350Feb 20 04:05 PM
Sherman Matthew LEVP & Chief Medical OfficerFeb 16 '24Sale15.622,61540,840108,739Feb 20 04:06 PM
Pitman JamaSVP, Chief Development OfficerFeb 16 '24Sale15.622,26735,40568,031Feb 20 04:05 PM
Martin Daniel C.Chief Commercial OfficerFeb 16 '24Sale15.622,26735,40555,118Feb 20 04:05 PM
Kelly Thomas PatrickChief Financial OfficerJan 16 '24Sale14.472,43535,23466,085Jan 18 04:15 PM
Sherman Matthew LEVP & Chief Medical OfficerJan 16 '24Sale14.472,43535,23494,079Jan 18 04:15 PM
Pitman JamaSVP, Chief Development OfficerJan 16 '24Sale14.471,62423,49950,573Jan 18 04:15 PM
Martin Daniel C.Chief Commercial OfficerJan 16 '24Sale14.471,62423,49947,660Jan 18 04:15 PM
Hoerter Steven L.President and CEODec 13 '23Sale15.3730,664471,21772,763Dec 14 04:05 PM
Kelly Thomas PatrickChief Financial OfficerDec 13 '23Sale15.372,79242,90568,520Dec 14 04:05 PM
Sherman Matthew LEVP & Chief Medical OfficerDec 13 '23Sale15.372,79242,90596,514Dec 14 04:05 PM
Martin Daniel C.Chief Commercial OfficerDec 13 '23Sale15.371,72726,53949,284Dec 14 04:05 PM
Pitman JamaSee RemarksDec 13 '23Sale15.371,66225,54052,197Dec 14 04:05 PM
Martin Daniel C.Chief Commercial OfficerNov 30 '23Sale12.5717,801223,75545,435Dec 01 04:05 PM
Hoerter Steven L.President and CEOOct 30 '23Sale12.0221,573259,25640,927Oct 31 04:09 PM
Sherman Matthew LEVP & Chief Medical OfficerOct 30 '23Sale12.022,36028,36290,628Oct 31 04:11 PM
Kelly Thomas PatrickChief Financial OfficerOct 30 '23Sale12.022,31627,83363,068Oct 31 04:09 PM
Martin Daniel C.Chief Commercial OfficerOct 30 '23Sale12.021,40716,90962,884Oct 31 04:10 PM
Pitman JamaSee RemarksOct 30 '23Sale12.021,40716,90948,283Oct 31 04:10 PM
Sherman Matthew LEVP & Chief Medical OfficerOct 02 '23Sale12.682,94237,30584,744Oct 04 04:05 PM